Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:50 - Any
Updated:2/8/2019
Start Date:July 5, 2017
End Date:January 2020
Contact:Santen Incorporated Clinical Operations
Email:clinicaltrials@santen.com
Phone:+1-415-268-9100

Use our guide to learn which trials are right for you!

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study

To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and
high dose) given in combination with Lucentis® in subjects with wet age-related macular
degeneration (AMD) compared with Lucentis® alone.


Inclusion Criteria:

- Provide signed written informed consent

- Diagnosis of active choroidal neovascularization secondary to wet AMD

- BCVA of 65 to 25 ETDRS letters (20/50 to 20/320) in the study eye

- BCVA of 25 ETDRS letters (20/320) or better in the fellow eye

Exclusion Criteria:

[Ocular]

- Use or anticipated use of any intravitreal, periocular or photodynamic therapy in the
study eye for the treatment of AMD within a specified timeframe prior to Visit 1 and
throughout the study

- Uncontrolled or advanced glaucoma, chronic hypotony or vitrectomy in the study eye

- Evidence of any other ocular disease other than exudative age-related macular
degeneration in the study eye that may confound the outcome of the study

- Need for ocular surgery in the study eye during the course of the study

- Presence or history of certain ocular or periocular pathology or conditions that could
limit the ability to perform examinations

[Non-ocular]

- Allergy or hypersensitivity to study drug product, fluorescein dye or other study
related procedures and medications

- Current or history of certain systemic conditions, abnormalities or therapies that
would render a subject a poor candidate for the study

- Participation in other investigational drug or device clinical trials within 30 days
prior to randomization or planning to participate in other investigational drug or
device clinical trials for the duration of the study

- Females who are pregnant or lactating and females of child-bearing potential who are
not using adequate contraceptive precautions and men who do not agree to practice an
acceptable method of contraception throughout the course of the study

- Unable to comply with study procedures or follow-up visits
We found this trial at
11
sites
Walnut Creek, California 94598
?
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Fort Myers, Florida 33912
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Gilbert, Arizona 85296
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Golden, Colorado 80401
?
mi
from
Golden, CO
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Makati City,
?
mi
from
Makati City,
Click here to add this to my saved trials
McAllen, Texas 78503
?
mi
from
McAllen, TX
Click here to add this to my saved trials
Mountain View, California 94040
?
mi
from
Mountain View, CA
Click here to add this to my saved trials
Rapid City, South Dakota 57701
?
mi
from
Rapid City, SD
Click here to add this to my saved trials